Recently, our real-world data study has mirrored outcomes from RCTs with SGLT2is, glucagon-like peptide-1 receptor agonists (GLP-1RAs) or combination therapy, with all three conferring mortality and cardiovascular protection in individuals with type 2 diabetes over 5 years [88]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.